drugset / Trial / NCT04233151

QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

NCT04233151

Phase 3 Unknown 590 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the treatment effect of QL1203 in combination with mFOLFOX6 compared to Placebo in combination with mFOLFOX6 as first line therapy for metastatic colorectal cancer.

Timeline

Start
2020-01-20
Primary completion
2024-12-31
Completion
2025-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject QL1203 Monoclonal antibody 6 mg/kg Intravenous
Background Leucovorin Small molecule 200 mg/m2
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background fluorouracil Small molecule 400 mg/m2 Intravenous
Background fluorouracil Small molecule 1200 mg/m2 Intravenous

Indications